.After elevating $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on everyone market.The Eli Lilly-partnered biotech plan to specify on the Nasdaq under the icon “BIOA,” depending on to records submitted along with the Securities and also Exchange Payment. The provider has not openly discussed an expected financial amount for the offering.The clinical-stage company promotes lead prospect azelaprag, an orally supplied tiny particle slated to get in period 2 testing in combination along with semaglutide– marketed by Novo Nordisk under brand Wegovy for fat loss– in the initial fifty percent of following year. Semaglutide is also offered as Ozempic and Rybelsus through Novo for diabetes.
Apelin receptor agonist azelaprag is made to incorporate effectively along with GLP-1 medicines, improving weight management while keeping muscle mass. The investigational medicine was actually discovered to become well-tolerated one of 265 people across 8 stage 1 trials, according to BioAge.Recently, BioAge gathered the assistance of Lilly to run a test mixing azelaprag with the Major Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetes as Mounjaro as well as Zepbound for weight management. The partners are actually presently administering a stage 2 trial of azelaprag and also tirzepatide, along with topline outcomes assumed in the third one-fourth of 2025.The biotech is actually likewise intending a the hormone insulin sensitiveness proof-of-concept test evaluating azelaprag as a monotherapy in the very first one-half of next year to support possible indication growth.
In addition, the company intends to ask the FDA for authorization in the 2nd half of 2025 to introduce individual screening for an NLRP3 prevention targeting metabolic health conditions as well as neuroinflammation.BioAge’s anticipated move to everyone market observes a minor uptick in considered biotech IPOs from Bicara Therapies and Zenas Biopharma. Zooming out, the current IPO landscape is a “blended image,” along with premium providers still debuting on the public markets, only in lowered amounts, according to PitchBook.